All AbMole products are for research use only, cannot be used for human consumption.
Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer.
| CAS Number | 1858168-59-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Related PD-1/PD-L1 Products |
|---|
| Avelumab (MSB0010718C)
Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1 |
| Panaxadiol
Panaxadiol exists in ginseng root and has neuroprotective and anti-tumor functions. Panaxadiol inhibits the expression of programmed cell death ligand-1 (PD-L1) and tumor proliferation. |
| Fraxinellone
Fraxinellone was isolated from the root bark of the brassica family Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor that inhibits HIF-1α synthesis without affecting HIF-1α degradation. Fraxinellone has potential for cancer immunity by targeting PD-L1. |
| BMS202
Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity. |
| Sulfamethoxypyridazine
Sulfamethoxypyridazine is a long-acting sulfonamide for treatment of Dermatitis herpetiformis. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
